Table 2.
Prevalence and antibacterial resistance of Gram negative pathogens in the study.
| No. | P/T | CAZ | M | IMP | ETP | CP | GM | TO | AMK | CO | SXT | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pseudomonas aeruginosa | 13 | 30.8 | 53.8 | 46.2 | 38.5 | 0 | 30.8 | 23.0 | 23.0 | 0 | 15.4 | 0 |
| ESBL(−) Klebsiella spp. | 10 | 40.0 | 20.0 | 0 | 0 | 0 | 10.0 | 30.0 | 0 | 12.5 | 0 | 20.0 |
| ESBL(+) Klebsiella spp. | 48 | 70.8 | 95.8 | 18.8 | 18.8 | 45.9 | 39.6 | 68.8 | 8.3 | 33.3 | 12.5 | 77.1 |
| ESBL (−) Escherichia coli | 10 | 0 | 30 | 0 | 0 | 0 | 10.0 | 20.0 | 10 | 0 | 0 | 40.0 |
| ESBL (+) Escherichia coli | 27 | 55.5 | 88.9 | 7.4 | 7.4 | 14.8 | 33.3 | 66.7 | 66.7 | 25.9 | 0 | 77.8 |
ESBL: extended spectrum beta lactamase; P/T: piperacillin tazobactam; CAZ: ceftazidime; M: meropenem; IMP: imipenem; ETP: ertapenem; CP: ciprofloxacin; GM: gentamicin; TO: tobramycin; AMK: amikacin; CO: colistin; SXT: sulphamethoxazole-trimetoprim.